Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ObjectivesTo analyse the adherence and impact of quality-of-care indicators (QCIs) in the management of Staphylococcus aureus bloodstream infection in a prospective and multicentre cohort.MethodsAnalysis of the prospective, multicentre international S. Aureus Collaboration cohort of S. Aureus bloodstream infection cases observed between January 2013 and April 2015. Multivariable analysis was performed to evaluate the impact of adherence to QCIs on 90-day mortality.ResultsA total of 1784 cases were included. Overall, 90-day mortality was 29.9% and mean follow-up period was 118 days. Adherence was 67% (n = 1180/1762) for follow-up blood cultures, 31% (n = 416/1342) for early focus control, 77.6% (n = 546/704) for performance of echocardiography, 75.5% (n = 1348/1784) for adequacy of targeted antimicrobial therapy, 88.6% (n = 851/960) for adequacy of treatment duration in non-complicated bloodstream infections and 61.2% (n = 366/598) in complicated bloodstream infections. Full bundle adherence was 18.4% (n = 328/1784). After controlling for immortal time bias and potential confounders, focus control (adjusted hazard ratio = 0.76; 95% CI, 0.59-0.99; p 0.038) and adequate targeted antimicrobial therapy (adjusted hazard ratio = 0.75; 95% CI, 0.61-0.91; p 0.004) were associated with low 90-day mortality.DiscussionAdherence to QCIs in S. Aureus bloodstream infection did not reach expected rates. Apart from the benefits of application as a bundle, focus control and adequate targeted therapy were independently associated with low mortality.

More information Original publication

DOI

10.1016/j.cmi.2022.10.019

Type

Journal article

Publication Date

2023-04-01T00:00:00+00:00

Volume

29

Pages

498 - 505

Total pages

7

Addresses

D, e, p, a, r, t, m, e, n, t, , o, f, , I, n, f, e, c, t, i, o, u, s, , D, i, s, e, a, s, e, s, ,, , H, o, s, p, i, t, a, l, , U, n, i, v, e, r, s, i, t, a, r, i, , d, e, , B, e, l, l, v, i, t, g, e, ,, , I, n, s, t, i, t, u, t, , d, ´, I, n, v, e, s, t, i, g, a, c, i, ó, , B, i, o, m, è, d, i, c, a, , d, e, , B, e, l, l, v, i, t, g, e, ,, , U, n, i, v, e, r, s, i, t, y, , o, f, , B, a, r, c, e, l, o, n, a, ,, , B, a, r, c, e, l, o, n, a, ,, , S, p, a, i, n, .

Keywords

International Staphylococcus Aureus Collaboration Study Group, The European Society of Clinical Microbiology and Infectious Diseases Study Group For Bloodstream Infections, Endocarditis And Sepsis, Humans, Staphylococcus aureus, Bacteremia, Staphylococcal Infections, Sepsis, Anti-Bacterial Agents, Prognosis, Prospective Studies